Mark Rutstein, MD Bio
Mark Rutstein, MD
As Head of Global Oncology Clinical Development, Mark and his team are responsible for the successful clinical development of the Daiichi Sankyo global oncology portfolio – ensuring oncology development has a strong talent base and a culture that values each individual. In his role, Mark partners closely with cross-functional partners and key stakeholders, internally and externally, to support the advancement of the global oncology pipeline.
Prior to joining Daiichi Sankyo, Mark served in a broad range of pharmaceutical positions including oncology drug development at Amgen, Eli-Lilly, Bayer Healthcare, and Bristol-Myers Squibb. Immediately prior to joining Daiichi Sankyo, served as Vice President, Oncology Development at Bristol Myers Squibb while providing oversight to the R&D of several oncology medicines across multiple clinical indications.
Mark has a passion for developing high performing clinical development teams and inspiring people to be the best version of themselves to make a difference for patients. He is driven with urgency to deliver new medicines to cancer patients with a high unmet clinical need.